Cargando…
Targeting c-Met in melanoma: Mechanism of resistance and efficacy of novel combinatorial inhibitor therapy
Numerous tyrosine kinase inhibitors (TKIs) targeting c-Met are currently in clinical trials for several cancers. Their efficacy is limited due to the development of resistance. The present study aims to elucidate this mechanism of c-Met TKI resistance by investigating key mTOR and Wnt signaling prot...
Autores principales: | Etnyre, Deven, Stone, Amanda L, Fong, Jason T, Jacobs, Ryan J, Uppada, Srijayaprakash B, Botting, Gregory M, Rajanna, Supriya, Moravec, David N, Shambannagari, Manohar R, Crees, Zachary, Girard, Jennifer, Bertram, Ceyda, Puri, Neelu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128856/ https://www.ncbi.nlm.nih.gov/pubmed/24914950 http://dx.doi.org/10.4161/cbt.29451 |
Ejemplares similares
-
Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and c-Met Inhibitor Resistance in Non-Small Cell Lung Cancer
por: Fong, Jason T., et al.
Publicado: (2013) -
hnRNP C1/C2 and Pur-beta proteins mediate induction of senescence by oligonucleotides homologous to the telomere overhang
por: Mulnix, Richard E, et al.
Publicado: (2013) -
Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy
por: Uppada, Srijayaprakash B, et al.
Publicado: (2013) -
Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
por: Botting, Gregory M., et al.
Publicado: (2015) -
EGFR/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer
por: Crees, Zachary D, et al.
Publicado: (2020)